Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CZP-SPEED study in moderate-to-severe rheumatoid arthritis
2011-000385-35Phase 4Completed
- Sponsor
- UCB
- Start
- Feb 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoint: Early clinical response predictive of Week 52 response. Started Feb 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-000385-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000385-35.